NEWSROOM

Servier certified Top Employer Europe 2022

20 / 01 / 2022Press release

Servier Group Reports Financial Year 2020/2021 Annual Results, R&D Strategy and Pipeline

18 / 01 / 2022Press release

Aqemia and Servier announce AI and quantum physics-driven drug discovery collaboration in immuno-oncology

03 / 12 / 2021Press release

Servier joins the Act4Nature International initiative

01 / 12 / 2021Press release

Pieris Pharmaceuticals and Servier announce dosing of first patient in phase 1/2 trial of 4-1BB/PD-L1 bispecific PRS-344/S095012

08 / 11 / 2021Press release

Servier and Guangdong Maijinjia Biotechnologies Co. LTD, and Ranger Biotechnologies enter into a Research Collaboration to develop a novel therapy for treating proteinopathies in rare neurodegenerative diseases

07 / 10 / 2021Press release

Servier and Neurochlore announce the main results of the two phase 3 clinical studies assessing bumetanide in the treatment of Autism Spectrum Disorders in children and adolescents

07 / 09 / 2021Press release

Servier and OSE Immunotherapeutics Announce Enrollment of First Patient in OSE-127/S95011 Phase 2 Clinical Trial in Sjögren’s Syndrome

25 / 08 / 2021Press release

Servier and Nymirum Announce Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics

12 / 07 / 2021Press release

Servier partners with BioLabs Global to open an incubator in Paris-Saclay for early stage life science companies

23 / 06 / 2021Press release

Servier and PRISM BioLab enter drug discovery collaboration for a novel target

16 / 06 / 2021Press release

Servier and Oncodesign announce the selection of a preclinical candidate as part of their collaboration targeting new treatments for Parkinson’s disease

14 / 06 / 2021Press release